iOmx Therapeutics Initiates Phase Ib with OMX-0407 Data from the successful Phase Ia dose escalation study showed that OMX-0407 monotherapy demonstrated a favorable safety profile and signs of anti-tumor activity, with one durable complete response in...

iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024 OMX-0407: clinical-stage, spectrum selective SIK kinase inhibitor with dual effect on tumor growth and immune evasionIOMX-0675: best-in-class antibody targeting immunosuppressive receptors LILRB1...

iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023 Discovery of novel immune checkpoints in the tumor microenvironment with iOTarg™ screening platformPredictive biomarker signature for lead product candidate OMX-0407 MUNICH, Germany, March 15, 2023 ...

iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022 MARTINSRIED / MUNICH, Germany, April 07, 2022 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint...